Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CES1 | P23141 | 4/20 | 0.70 |
| ▸ | ACHE | P22303 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | ALDH3A1 | P30838 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.69 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.69 |
| ▸ | BCHE | P06276 | 2/20 | 0.68 |
| ▸ | CES2 | O00748 | 1/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937979 | 1.00 | CHRM5 (1.00) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL18288159 | 0.87 | CES1 (0.90) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL18974138 | 0.85 | CHRM5 (0.74) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL4597340 | 0.85 | CHRM5 (0.73) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL30774308 | 0.83 | CES1 (0.77) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL4597810 | 0.83 | CES1 (0.77) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL28093749 | 0.83 | CHRM5 (0.71) | CHRM5CES1ALDH1A1ALDH3A1CHRM1 | |
| SCHEMBL28094130 | 0.83 | CHRM5 (0.71) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL29506660 | 0.82 | ALDH1A1 (1.00) | CHRM5CES1ACHEALDH1A1ALDH3A1 | |
| SCHEMBL2087729 | 0.82 | ALDH1A1 (1.00) | CHRM5CES1ACHEALDH1A1ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118125961-A | 1- (4-Trifluoromethyl-benzyl) -isatin derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-06-04 | — | — | CN | claimed |
| CN-118125961-A | 1- (4-Trifluoromethyl-benzyl) -isatin derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-06-04 | — | — | CN | disclosed |
| CN-118125961-A | 1- (4-Trifluoromethyl-benzyl) -isatin derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-06-04 | — | — | CN | disclosed |
| CN-118125961-A | 1- (4-Trifluoromethyl-benzyl) -isatin derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-06-04 | — | — | CN | disclosed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| WO-2008074078-A1 | SELECTIVELY DELIVERABLE ISATIN-BASED CYTOTOXIC AGENTS | UNIVERSITY OF WOLLONGONG (AU) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CHRM5 355/4885CES1 4183/4885ACHE 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.